![](https://endpts.com/wp-content/uploads/2023/05/Athena-Countouriotis-Avenzo-website-via-Nasdaq-tile.jpg)
Athena Countouriotis, Avenzo Therapeutics CEO (website via Nasdaq)
Ex-Turning Point execs plan to have their next bet, Avenzo, on the Nasdaq next summer
The crew at Turning Point Therapeutics is back together for a new biotech that wants to acquire early-stage oncology small molecules, including antibody drug conjugates …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.